Innovent Biologics (HKG:1801) terminated its agreement to issue and sell over 12.8 million new series Pre-A preferred shares of Fortvita Biologics to Lostrancos Ventures following the feedback from its shareholders, a Sunday Hong Kong bourse filing said.
The company had agreed to issue and sell the said shares to the purchaser for $20.5 million on Oct. 25 in order to increase its international business.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。